ConductScience.org, home

Paper35936699

The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.

Zhang DL and 10 others. Front Oncol, 2022. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Papers, record 35936699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35936699

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.
PubMed
Journal
Front Oncol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.4
iCite
Revised in PubMed
2022-08-09
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang DLDa-Li
2Feng DNDan-Ni
3He XXi
4Zhang XFXiao-Feng
5Li LXLi-Xin
6Li ZJZhi-Jie
7Niu XFXiao-Feng
8Zhuang YLYun-Long
9Liu ZWZhen-Wen
10Gao XDXu-Dong
11Wang HBHong-Bo

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111391528Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001https://conductscience.org/library/papers/11391528PubMed
223995766Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience.Eur J Gastroenterol Hepatol2014https://conductscience.org/library/papers/23995766PubMed
335002724Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.Front Pharmacol2021https://conductscience.org/library/papers/35002724PubMed
428989060Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.Gastroenterology2018https://conductscience.org/library/papers/28989060PubMed
535550167Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.Pharmacol Res2022https://conductscience.org/library/papers/35550167PubMed
631850994Locoregional Therapy, Pathologic Response, and HCC Recurrence After Liver Transplantation: Highlighting Success and Looking Toward the Future.Ann Surg2020https://conductscience.org/library/papers/31850994PubMed
734768358
The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria.
J Clin Med2021https://conductscience.org/library/papers/34768358PubMed
828859222Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.Hepatology2018https://conductscience.org/library/papers/28859222PubMed
98594428Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996https://conductscience.org/library/papers/8594428PubMed
1030166858Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.World J Gastroenterol2018https://conductscience.org/library/papers/30166858PubMed
1133995073Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway.Front Pharmacol2021https://conductscience.org/library/papers/33995073PubMed
1234722189Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.J Clin Transl Hepatol2021https://conductscience.org/library/papers/34722189PubMed
1334513717Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging.Front Oncol2021https://conductscience.org/library/papers/34513717PubMed
1435605812Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells.Pharmacol Res2022https://conductscience.org/library/papers/35605812PubMed
1528983565The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.JAMA Oncol2017https://conductscience.org/library/papers/28983565PubMed
1622432733Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma.Aliment Pharmacol Ther2012https://conductscience.org/library/papers/22432733PubMed
1731774468Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/31774468PubMed
1831054040Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma.Ann Surg Oncol2019https://conductscience.org/library/papers/31054040PubMed
1931511501SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.Cell Death Dis2019https://conductscience.org/library/papers/31511501PubMed
2032801748Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents.Onco Targets Ther2020https://conductscience.org/library/papers/32801748PubMed

See all 45 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42394399Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Aliment Pharmacol Ther2026https://conductscience.org/library/papers/42394399PubMed
41312914Prognostic Significance of Up-to-Seven Criteria Versus Milan Criteria for Hepatocellular Carcinoma Patients Undergoing Resection or Locoregional Therapy: A Systematic Review and Meta-Analysis.Asian Pac J Cancer Prev2025https://conductscience.org/library/papers/41312914PubMed
38927509Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence.Biomedicines2024https://conductscience.org/library/papers/38927509PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
TENM110178PubTator's text mininghttps://conductscience.org/library/genes/10178NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35936699

GET https://conductscience.org/api/papers/v1/35936699/references?page=2